Quinazoline Compounds Selective Sodium Channel Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium channel blockers for pain management suffer from lack of selectivity, leading to central nervous system and cardiovascular side effects, and interactions with hERG, Cytochrome P450, and calcium channels, necessitating the development of compounds with improved selectivity and reduced activity against specific channels.
Innovation Solution
Development of compounds with specific structural features that selectively inhibit sodium channels, particularly NaV 1.8, while minimizing activity against hERG, Cytochrome P450, and calcium channels, enhancing pharmacokinetic and pharmacodynamic properties for improved therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current sodium channel blockers are used for pain management, then pain relief is achieved, but central nervous system and cardiovascular side effects occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (quinazoline core with particular substituent patterns) that confer selective affinity for sodium channels over other targets. The molecular structure is optimized to interact specifically with the sodium channel binding site while avoiding hERG, calcium channel, and Cytochrome P450 interactions, thereby achieving pain relief with reduced side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations on the quinazoline scaffold) to modulate selectivity. By adjusting these molecular parameters, the compounds achieve optimal binding affinity for sodium channels while minimizing off-target effects, resolving the contradiction between efficacy and safety
2Reliability
If current sodium channel blockers are used, then pain management is provided, but drug interactions occur with hERG, Cytochrome P450, and calcium channels
Solution Approach 1:
The patent uses local quality by designing the quinazoline compound structure with specific local chemical features that enable selective interaction with sodium channels. The molecular architecture is tailored to fit the sodium channel binding pocket while lacking the structural motifs required for hERG, calcium channel, or Cytochrome P450 binding, thereby preventing drug interactions while maintaining therapeutic efficacy
3Object-affected harmful factors
If compounds with high selectivity for sodium channels are developed, then side effects are reduced, but pharmacokinetic and pharmacodynamic optimization becomes more challenging
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: a quinazoline core providing sodium channel selectivity, and separate substituent groups (R1-R6) that can be independently optimized for pharmacokinetic properties. This modular approach allows selective optimization of each component, reducing side effects while managing structural complexity through systematic design
Data Source
AI summary
The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.